0 47

Cited 4 times in

Maximum surgical resection and adjuvant intensity-modulated radiotherapy with simultaneous integrated boost for skull base chordoma

 Jun Won Kim  ;  Chang-Ok Suh  ;  Chang-Ki Hong  ;  Eui Hyun Kim  ;  Ik Jae Lee  ;  Jaeho Cho  ;  Kyu-Sung Lee 
 Acta Neurochirurgica, Vol.159(10) : 1825-1834, 2017 
Journal Title
 Acta Neurochirurgica 
Issue Date
Adolescent ; Adult ; Chordoma/radiotherapy ; Chordoma/surgery ; Chordoma/therapy* ; Combined Modality Therapy ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/radiotherapy ; Neoplasm Recurrence, Local/surgery ; Neoplasm Recurrence, Local/therapy* ; Neurosurgical Procedures ; Radiotherapy Dosage ; Radiotherapy Planning, Computer-Assisted ; Radiotherapy, Intensity-Modulated* ; Skull Base/surgery* ; Skull Base Neoplasms/radiotherapy ; Skull Base Neoplasms/surgery ; Skull Base Neoplasms/therapy* ; Survival Rate ; Treatment Outcome
Adjuvant radiotherapy ; Clivus chordoma ; IMRT with simultaneous integrated boost ; Maximum surgical resection
BACKGROUND: Local recurrence is common after surgical resection of clivus chordoma. We report the results of maximum surgical resection followed by intensity-modulated radiotherapy with simultaneous integrated boost (IMRT-SIB). METHODS: We reviewed 14 consecutive clivus chordoma cases undergoing postoperative IMRT-SIB using the institutional protocol between 2005 and 2013. Total and near-total resections were achieved in 11 patients (78.6 %), partial in 2 patients (14.3 %), and 1 patient (7.1 %) received RT for recurrent tumor after total resection. Gross residual or the high-risk area defined the planning target volume (PTV)1; PTV2 was the postoperative tumor bed plus a 3-5-mm margin, and PTV3 was PTV2 plus a 5-10 mm margin. A moderate hypofractionation schedule was used: doses to PTV1, PTV2 and PTV3 were 3.9 Gy, 3.15 Gy and 2.8 Gy through 15 fractions for the first two patients, and the rest received 2.5 Gy, 2.2 Gy and 1.8 Gy through 25 fractions. The biologically equivalent dose in 2-Gy fractions (EQD2) was 65-68 Gy for PTV1, 52-56 Gy for PTV2, and 44.3-44.8 Gy for PTV3. RESULTS: Median follow-up was 41 months. Eight patients were free of disease for median 42.5 months (range 23-91 months), four patients had stable disease for median 60.5 months (range 39-113 months), and 1 patient showed partial response for 38 months after RT. Local progression was seen in one patient who received EQD2 67.8 Gy after partial resection. Estimated 5-year progression-free and overall survival rates were 92.9 %. Surgery improved the neurologic deficit in six patients, and IMRT-SIB was well tolerated without lasting toxicity. CONCLUSION: Our experience suggests that maximum resection and high-dose IMRT-SIB can achieve local control without significant morbidities.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
김의현(Kim, Eui Hyun) ORCID logo https://orcid.org/0000-0002-2523-7122
김준원(Kim, Jun Won) ORCID logo https://orcid.org/0000-0003-1358-364X
서창옥(Suh, Chang Ok)
이규성(Lee, Kyu Sung)
이익재(Lee, Ik Jae) ORCID logo https://orcid.org/0000-0001-7165-3373
조재호(Cho, Jae Ho) ORCID logo https://orcid.org/0000-0001-9966-5157
홍창기(Hong, Chang Ki)
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.